Consensus conference results on contraception in women beyond 40 years of age
The objective is to develop expert consensus to inform clinical decision-making in the use of hormonal contraceptives in women over 40 years of age. A multidisciplinary panel organised by the Italian Society of Contraception performed a systematic literature review up to October 2024, defining the p...
Uloženo v:
| Vydáno v: | The European journal of contraception & reproductive health care Ročník 30; číslo 6; s. 304 - 318 |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
Taylor & Francis Ltd
01.12.2025
|
| Témata: | |
| ISSN: | 1362-5187, 1473-0782, 1473-0782 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The objective is to develop expert consensus to inform clinical decision-making in the use of hormonal contraceptives in women over 40 years of age.
A multidisciplinary panel organised by the Italian Society of Contraception performed a systematic literature review up to October 2024, defining the priorities in the choice of a contraceptive and its effects on cardiovascular risk, menstrual bleeding, bone health, and sexual function associated with hormonal contraception in women over 40. Statements summarising the findings were discussed and refined in a dedicated expert meeting. Final statements were presented and subjected to anonymous voting at a national congress, where consensus was defined as a minimum of 75% agreement.
Ninety-five to ninety-nine percent of participants endorsed seven consensus statements. Cardiovascular safety is recognised as the primary factor in the selection of contraceptives. The use of progestogen-only methods is considered safe for cardiovascular risk. Combined hormonal contraceptives utilising natural oestrogens or 20 mcg ethynylestradiol in conjunction with non-androgenic progestins are considered more advantageous for the cardiovascular risk profile. The levonorgestrel intrauterine device, oestradiol valerate/dienogest, and the combined contraceptive vaginal ring are identified as the most effective options for menstrual management. The type of hormone and its route of administration can influence sexual function, with implants and vaginal rings showing positive effects. Combined hormonal contraceptives demonstrate protective effects on bone density, whereas progestogen-only methods exhibit a neutral impact.
This Italian consensus provides evidence-based guidance on hormonal contraceptive choices for women over 40, incorporating non-contraceptive effects to support individualised care during perimenopause. |
|---|---|
| AbstractList | Objective: The objective is to develop expert consensus to inform clinical decision-making in the use of hormonal contraceptives in women over 40 years of age. Methods: A multidisciplinary panel organised by the Italian Society of Contraception performed a systematic literature review up to October 2024, defining the priorities in the choice of a contraceptive and its effects on cardiovascular risk, menstrual bleeding, bone health, and sexual function associated with hormonal contraception in women over 40. Statements summarising the findings were discussed and refined in a dedicated expert meeting. Final statements were presented and subjected to anonymous voting at a national congress, where consensus was defined as a minimum of 75% agreement. Results: Ninety-five to ninety-nine percent of participants endorsed seven consensus statements. Cardiovascular safety is recognised as the primary factor in the selection of contraceptives. The use of progestogen-only methods is considered safe for cardiovascular risk. Combined hormonal contraceptives utilising natural oestrogens or 20 mcg ethynylestradiol in conjunction with non-androgenic progestins are considered more advantageous for the cardiovascular risk profile. The levonorgestrel intrauterine device, oestradiol valerate/dienogest, and the combined contraceptive vaginal ring are identified as the most effective options for menstrual management. The type of hormone and its route of administration can influence sexual function, with implants and vaginal rings showing positive effects. Combined hormonal contraceptives demonstrate protective effects on bone density, whereas progestogen-only methods exhibit a neutral impact. Conclusions: This Italian consensus provides evidence-based guidance on hormonal contraceptive choices for women over 40, incorporating non-contraceptive effects to support individualised care during perimenopause. Objective: The objective is to develop expert consensus to inform clinical decision-making in the use of hormonal contraceptives in women over 40 years of age. Methods: A multidisciplinary panel organised by the Italian Society of Contraception performed a systematic literature review up to October 2024, defining the priorities in the choice of a contraceptive and its effects on cardiovascular risk, menstrual bleeding, bone health, and sexual function associated with hormonal contraception in women over 40. Statements summarising the findings were discussed and refined in a dedicated expert meeting. Final statements were presented and subjected to anonymous voting at a national congress, where consensus was defined as a minimum of 75% agreement. Results: Ninety-five to ninety-nine percent of participants endorsed seven consensus statements. Cardiovascular safety is recognised as the primary factor in the selection of contraceptives. The use of progestogen-only methods is considered safe for cardiovascular risk. Combined hormonal contraceptives utilising natural oestrogens or 20 mcg ethynylestradiol in conjunction with non-androgenic progestins are considered more advantageous for the cardiovascular risk profile. The levonorgestrel intrauterine device, oestradiol valerate/dienogest, and the combined contraceptive vaginal ring are identified as the most effective options for menstrual management. The type of hormone and its route of administration can influence sexual function, with implants and vaginal rings showing positive effects. Combined hormonal contraceptives demonstrate protective effects on bone density, whereas progestogen-only methods exhibit a neutral impact. Conclusions: This Italian consensus provides evidence-based guidance on hormonal contraceptive choices for women over 40, incorporating non-contraceptive effects to support individualised care during perimenopause.Objective: The objective is to develop expert consensus to inform clinical decision-making in the use of hormonal contraceptives in women over 40 years of age. Methods: A multidisciplinary panel organised by the Italian Society of Contraception performed a systematic literature review up to October 2024, defining the priorities in the choice of a contraceptive and its effects on cardiovascular risk, menstrual bleeding, bone health, and sexual function associated with hormonal contraception in women over 40. Statements summarising the findings were discussed and refined in a dedicated expert meeting. Final statements were presented and subjected to anonymous voting at a national congress, where consensus was defined as a minimum of 75% agreement. Results: Ninety-five to ninety-nine percent of participants endorsed seven consensus statements. Cardiovascular safety is recognised as the primary factor in the selection of contraceptives. The use of progestogen-only methods is considered safe for cardiovascular risk. Combined hormonal contraceptives utilising natural oestrogens or 20 mcg ethynylestradiol in conjunction with non-androgenic progestins are considered more advantageous for the cardiovascular risk profile. The levonorgestrel intrauterine device, oestradiol valerate/dienogest, and the combined contraceptive vaginal ring are identified as the most effective options for menstrual management. The type of hormone and its route of administration can influence sexual function, with implants and vaginal rings showing positive effects. Combined hormonal contraceptives demonstrate protective effects on bone density, whereas progestogen-only methods exhibit a neutral impact. Conclusions: This Italian consensus provides evidence-based guidance on hormonal contraceptive choices for women over 40, incorporating non-contraceptive effects to support individualised care during perimenopause. The objective is to develop expert consensus to inform clinical decision-making in the use of hormonal contraceptives in women over 40 years of age. A multidisciplinary panel organised by the Italian Society of Contraception performed a systematic literature review up to October 2024, defining the priorities in the choice of a contraceptive and its effects on cardiovascular risk, menstrual bleeding, bone health, and sexual function associated with hormonal contraception in women over 40. Statements summarising the findings were discussed and refined in a dedicated expert meeting. Final statements were presented and subjected to anonymous voting at a national congress, where consensus was defined as a minimum of 75% agreement. Ninety-five to ninety-nine percent of participants endorsed seven consensus statements. Cardiovascular safety is recognised as the primary factor in the selection of contraceptives. The use of progestogen-only methods is considered safe for cardiovascular risk. Combined hormonal contraceptives utilising natural oestrogens or 20 mcg ethynylestradiol in conjunction with non-androgenic progestins are considered more advantageous for the cardiovascular risk profile. The levonorgestrel intrauterine device, oestradiol valerate/dienogest, and the combined contraceptive vaginal ring are identified as the most effective options for menstrual management. The type of hormone and its route of administration can influence sexual function, with implants and vaginal rings showing positive effects. Combined hormonal contraceptives demonstrate protective effects on bone density, whereas progestogen-only methods exhibit a neutral impact. This Italian consensus provides evidence-based guidance on hormonal contraceptive choices for women over 40, incorporating non-contraceptive effects to support individualised care during perimenopause. |
| Author | Guida, Maurizio Londero, Ambrogio Pietro Bonaccorsi, Gloria Cagnacci, Angelo Gambera, Alessandro Fruzzetti, Franca Bruni, Vincenzina |
| Author_xml | – sequence: 1 givenname: Angelo orcidid: 0000-0003-2714-623X surname: Cagnacci fullname: Cagnacci, Angelo – sequence: 2 givenname: Franca surname: Fruzzetti fullname: Fruzzetti, Franca – sequence: 3 givenname: Vincenzina surname: Bruni fullname: Bruni, Vincenzina – sequence: 4 givenname: Alessandro surname: Gambera fullname: Gambera, Alessandro – sequence: 5 givenname: Maurizio surname: Guida fullname: Guida, Maurizio – sequence: 6 givenname: Gloria surname: Bonaccorsi fullname: Bonaccorsi, Gloria – sequence: 7 givenname: Ambrogio Pietro surname: Londero fullname: Londero, Ambrogio Pietro |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40838950$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kctOwzAQRS1UBG3hE0CR2LBJ8TN2xApVvCQQG1hbjjNBQYld7ESof4-jthsWrMZjnesZ37tAM-cdIHRB8IpghW8IK6ggSq4opmJFBedS8CM0J1yyHEtFZ-mcmHyCTtEixi-MCeOsOEGnHCumSoHn6HXtXQQXx5hZ7xoI4CxkAeLYDTHzbrodgrGwGdrUtS778T24rIKtd3XGcbYFExLZZOYTztBxY7oI5_u6RB8P9-_rp_zl7fF5ffeSW8bKIReVYrbmtkhfKHhZgQFJlJAVrxkj3FJJcGNVqajCFRBiFGFKgqgLKm1JFFui6927m-C_R4iD7ttooeuMAz9GzSgvOKFc0oRe_UG__Bhc2i5RUgiKuRCJutxTY9VDrTeh7U3Y6oNRCbjdATb4GAM02raDmTxJ7rSdJlhPsehDLHqKRe9jSWrxR30Y8L_uF17ejKk |
| CitedBy_id | crossref_primary_10_3390_ph18091402 |
| Cites_doi | 10.1136/bmjsrh-2022-PoP 10.1016/j.jogc.2015.12.003 10.1111/jsm.12310 10.1210/jc.2007-1876 10.1016/j.contraception.2025.110861 10.3389/fendo.2020.00334 10.15761/FWH.1000178 10.1161/STROKEAHA.108.538405 10.1002/14651858.CD013180.pub2 10.1080/09513590.2016.1249841 10.1016/j.gofs.2018.10.008 10.1016/j.maturitas.2022.09.011 10.1002/14651858.CD013651.pub2 10.3390/jcm8060908 10.1016/j.contraception.2011.02.013 10.1016/j.contraception.2023.110310 10.1016/j.jogc.2015.12.002 10.1093/humupd/5.6.721 10.1002/14651858.CD003989.pub5 10.1136/bmj-2024-082801 10.1136/bmj.d6423 10.1093/humupd/dmi046 10.3109/13625187.2011.591456 10.1016/S0015-0282(99)80014-4 10.1002/14651858.CD009849.pub3 10.1038/ijo.2008.25 10.1002/phar.2657 10.1155/2019/3726957 10.1093/humrep/deh686 10.1007/s00404-019-05340-4 10.1016/j.maturitas.2005.10.007 10.1016/j.contraception.2011.10.007 10.1136/bmj.e2990 10.1016/j.beem.2023.101822 10.1097/AOG.0b013e3181ca4b3a 10.1016/j.fertnstert.2014.03.004 10.1016/j.ejogrb.2016.05.009 10.1016/j.fertnstert.2016.09.027 10.3390/ph18010061 10.1136/jfprhc-2015-101375 10.1007/s00198-019-05103-6 10.3390/jcm11030810 10.2147/IJWH.S65481 10.1272/jnms.79.190 10.1097/GME.0000000000001427 10.1080/13625187.2023.2284085 10.1016/j.contraception.2016.04.014 10.1056/NEJMoa1111840 10.15585/mmwr.rr7304a1 10.1016/s0010-7824(02)00473-0 10.1080/13625187.2002.11949332 10.1080/13625187.2024.2369833 10.4068/cmj.2018.54.3.153 10.1016/j.maturitas.2003.09.014 10.1097/gme.0b013e3181aa192d 10.1016/s0029-7844(00)00930-3 10.1056/NEJMoa1204724 10.1002/14651858.CD002126.pub4 10.1155/2019/9701384 10.1097/AOG.0b013e3182118ac3 10.1080/13625187.2024.2332302 10.1177/2047487318774847 10.1016/j.contraception.2005.02.002 10.1080/13697137.2018.1540566 10.3109/09513590.2014.922947 10.3109/13625189709167466 10.1007/s00404-015-3784-0 10.1016/0010-7824(95)00226-x 10.1093/humrep/del162 10.2165/00003495-200363050-00003 10.20452/pamw.2128 10.1016/j.coemr.2023.100435 10.23736/S0026-4784.19.04469-1 10.1111/j.1743-6109.2011.02409.x 10.1371/journal.pmed.1004326 10.1055/a-1919-9558 10.1016/j.contraception.2016.06.010 10.23736/S0026-4784.18.04291-0 10.1089/jwh.2016.5801 10.1097/AOG.0000000000000019 10.1093/humrep/deq043 10.1002/14651858.CD011054.pub2 10.1097/AOG.0000000000004899 10.1001/jama.2024.28778 10.1097/00003081-199538040-00019 10.1016/S0140-6736(00)03615-1 10.1080/13625187.2020.1731734 10.1080/13697137.2019.1632284 10.3389/fendo.2024.1428597 10.3109/01443615.2015.1024210 10.1111/aogs.14384 10.2196/63683 10.23736/S2724-606X.20.04688-2 10.1093/humrep/15.1.118 10.1093/humrep/dei457 10.1002/14651858.CD006033.pub5 |
| ContentType | Journal Article |
| Copyright | 2025 The European Society of Contraception and Reproductive Health |
| Copyright_xml | – notice: 2025 The European Society of Contraception and Reproductive Health |
| CorporateAuthor | for the Italian Society of Contraception (S.I.C.) Italian Society of Contraception (S.I.C.) |
| CorporateAuthor_xml | – name: for the Italian Society of Contraception (S.I.C.) – name: Italian Society of Contraception (S.I.C.) |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 |
| DOI | 10.1080/13625187.2025.2544754 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1473-0782 |
| EndPage | 318 |
| ExternalDocumentID | 40838950 10_1080_13625187_2025_2544754 |
| Genre | Review Consensus Development Conference Systematic Review Journal Article |
| GeographicLocations | Italy |
| GeographicLocations_xml | – name: Italy |
| GroupedDBID | --- 00X 03L 0R~ 123 29G 36B 4.4 6PF AAGDL AALUX AAMIU AAPUL AAQRR AAWTL AAYXX ABBKH ABDBF ABEIZ ABIVO ABJNI ABLIJ ABLKL ABUPF ABWVI ABXYU ACENM ACGEJ ACGFS ADCVX ADRBQ ADXPE AECIN AENEX AEOZL AFKVX AFRVT AGDLA AGFJD AGRBW AGYJP AHMBA AIJEM AIRBT AJWEG AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU ALYBC AMDAE BABNJ BLEHA BOHLJ CCCUG CITATION CS3 DKSSO DU5 EAP EBS EMB ESX F5P H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M4Z O9- RNANH RRB RVRKI RWL TAE TASJS TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ TUS UEQFS V1S ~1N 53G 5VS 7X7 88E 8AO 8FI 8FJ 8G5 AAJKZ AALIY AAORF AAPXX ABUWG ABWCV ABZEW ACIEZ ACKZS ACOPL ACUHS ADBBV ADFOM ADFZZ AEIIZ AFFHD AFKRA AFLEI AJVHN AWYRJ AZQEC BENPR BPHCQ BRMBE BVXVI CAG CCPQU CGR COF CUY CVF CYYVM CZDIS DRXRE DWQXO DWTOO EAS EBC EBD ECM EIF EJD EMK EMOBN EPL FYUFA GNUQQ GUQSH HMCUK JENTW M1P M2O M44 NPM NUSFT PADUT PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO QQXMO S0X SV3 UKHRP K9. 7X8 AQTUD |
| ID | FETCH-LOGICAL-c339t-5b83cd4c6625649beae71857b4d3314c2710fc898280be11a81387e5d627c9183 |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001554929600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1362-5187 1473-0782 |
| IngestDate | Sat Nov 01 14:26:19 EDT 2025 Mon Dec 01 18:12:41 EST 2025 Thu Nov 27 01:51:53 EST 2025 Tue Nov 18 20:47:28 EST 2025 Thu Nov 27 00:49:29 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | hormonal contraception consensus statement bone metabolism sexuality menstrual bleeding Perimenopause cardiovascular risk |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c339t-5b83cd4c6625649beae71857b4d3314c2710fc898280be11a81387e5d627c9183 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-2714-623X |
| PMID | 40838950 |
| PQID | 3275520455 |
| PQPubID | 44424 |
| PageCount | 15 |
| ParticipantIDs | proquest_miscellaneous_3246412472 proquest_journals_3275520455 pubmed_primary_40838950 crossref_citationtrail_10_1080_13625187_2025_2544754 crossref_primary_10_1080_13625187_2025_2544754 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-Dec |
| PublicationDateYYYYMMDD | 2025-12-01 |
| PublicationDate_xml | – month: 12 year: 2025 text: 2025-Dec |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Carnforth |
| PublicationTitle | The European journal of contraception & reproductive health care |
| PublicationTitleAlternate | Eur J Contracept Reprod Health Care |
| PublicationYear | 2025 |
| Publisher | Taylor & Francis Ltd |
| Publisher_xml | – name: Taylor & Francis Ltd |
| References | e_1_3_5_27_1 e_1_3_5_100_1 e_1_3_5_23_1 Australian Commission on Safety and Quality in Health Care (e_1_3_5_44_1) 2024 e_1_3_5_46_1 e_1_3_5_69_1 e_1_3_5_88_1 e_1_3_5_61_1 e_1_3_5_80_1 e_1_3_5_42_1 e_1_3_5_65_1 e_1_3_5_84_1 e_1_3_5_9_1 e_1_3_5_5_1 e_1_3_5_39_1 e_1_3_5_16_1 e_1_3_5_35_1 e_1_3_5_12_1 e_1_3_5_77_1 e_1_3_5_58_1 e_1_3_5_50_1 e_1_3_5_92_1 e_1_3_5_73_1 e_1_3_5_54_1 e_1_3_5_96_1 e_1_3_5_31_1 e_1_3_5_101_1 e_1_3_5_28_1 World Health Organization (e_1_3_5_3_1) 2015 e_1_3_5_24_1 e_1_3_5_66_1 e_1_3_5_47_1 e_1_3_5_89_1 Faculty of Sexual and Reproductive Healthcare (e_1_3_5_102_1) 2019 e_1_3_5_81_1 e_1_3_5_62_1 e_1_3_5_43_1 e_1_3_5_85_1 e_1_3_5_8_1 e_1_3_5_20_1 e_1_3_5_4_1 e_1_3_5_17_1 e_1_3_5_13_1 e_1_3_5_36_1 e_1_3_5_55_1 e_1_3_5_78_1 e_1_3_5_59_1 e_1_3_5_70_1 e_1_3_5_93_1 e_1_3_5_51_1 e_1_3_5_74_1 e_1_3_5_97_1 e_1_3_5_32_1 e_1_3_5_29_1 e_1_3_5_25_1 e_1_3_5_67_1 Gambacciani M (e_1_3_5_14_1) 1994; 83 e_1_3_5_48_1 e_1_3_5_82_1 e_1_3_5_40_1 e_1_3_5_63_1 e_1_3_5_86_1 Faculty of Sexual & Reproductive Healthcare (e_1_3_5_2_1) 2023 e_1_3_5_21_1 e_1_3_5_7_1 e_1_3_5_18_1 e_1_3_5_37_1 e_1_3_5_33_1 e_1_3_5_56_1 e_1_3_5_79_1 e_1_3_5_94_1 e_1_3_5_71_1 e_1_3_5_52_1 e_1_3_5_98_1 e_1_3_5_75_1 e_1_3_5_10_1 e_1_3_5_90_1 e_1_3_5_26_1 e_1_3_5_22_1 e_1_3_5_68_1 e_1_3_5_49_1 e_1_3_5_103_1 e_1_3_5_83_1 e_1_3_5_60_1 e_1_3_5_41_1 e_1_3_5_87_1 e_1_3_5_64_1 e_1_3_5_6_1 e_1_3_5_38_1 e_1_3_5_15_1 e_1_3_5_11_1 e_1_3_5_34_1 e_1_3_5_57_1 e_1_3_5_99_1 e_1_3_5_19_1 National Guideline Alliance (Great Britain) (e_1_3_5_45_1) 2021 e_1_3_5_72_1 e_1_3_5_91_1 e_1_3_5_53_1 e_1_3_5_76_1 e_1_3_5_95_1 e_1_3_5_30_1 |
| References_xml | – ident: e_1_3_5_60_1 doi: 10.1136/bmjsrh-2022-PoP – ident: e_1_3_5_103_1 doi: 10.1016/j.jogc.2015.12.003 – volume-title: Heavy menstrual bleeding clinical care standard year: 2024 ident: e_1_3_5_44_1 – ident: e_1_3_5_70_1 doi: 10.1111/jsm.12310 – ident: e_1_3_5_13_1 doi: 10.1210/jc.2007-1876 – ident: e_1_3_5_36_1 doi: 10.1016/j.contraception.2025.110861 – ident: e_1_3_5_81_1 doi: 10.3389/fendo.2020.00334 – ident: e_1_3_5_27_1 doi: 10.15761/FWH.1000178 – ident: e_1_3_5_30_1 doi: 10.1161/STROKEAHA.108.538405 – ident: e_1_3_5_43_1 doi: 10.1002/14651858.CD013180.pub2 – ident: e_1_3_5_64_1 doi: 10.1080/09513590.2016.1249841 – ident: e_1_3_5_99_1 doi: 10.1016/j.gofs.2018.10.008 – ident: e_1_3_5_86_1 doi: 10.1016/j.maturitas.2022.09.011 – ident: e_1_3_5_42_1 doi: 10.1002/14651858.CD013651.pub2 – ident: e_1_3_5_61_1 doi: 10.3390/jcm8060908 – ident: e_1_3_5_71_1 doi: 10.1016/j.contraception.2011.02.013 – ident: e_1_3_5_40_1 doi: 10.1016/j.contraception.2023.110310 – ident: e_1_3_5_101_1 doi: 10.1016/j.jogc.2015.12.002 – ident: e_1_3_5_12_1 doi: 10.1093/humupd/5.6.721 – ident: e_1_3_5_55_1 doi: 10.1002/14651858.CD003989.pub5 – ident: e_1_3_5_31_1 doi: 10.1136/bmj-2024-082801 – ident: e_1_3_5_21_1 doi: 10.1136/bmj.d6423 – ident: e_1_3_5_77_1 doi: 10.1093/humupd/dmi046 – ident: e_1_3_5_49_1 doi: 10.3109/13625187.2011.591456 – ident: e_1_3_5_24_1 doi: 10.1016/S0015-0282(99)80014-4 – ident: e_1_3_5_97_1 doi: 10.1002/14651858.CD009849.pub3 – ident: e_1_3_5_11_1 doi: 10.1038/ijo.2008.25 – ident: e_1_3_5_80_1 doi: 10.1002/phar.2657 – ident: e_1_3_5_65_1 doi: 10.1155/2019/3726957 – volume-title: Medical eligibility criteria for contraceptive use year: 2015 ident: e_1_3_5_3_1 – ident: e_1_3_5_63_1 doi: 10.1093/humrep/deh686 – ident: e_1_3_5_59_1 doi: 10.1007/s00404-019-05340-4 – ident: e_1_3_5_17_1 doi: 10.1016/j.maturitas.2005.10.007 – ident: e_1_3_5_72_1 doi: 10.1016/j.contraception.2011.10.007 – ident: e_1_3_5_22_1 doi: 10.1136/bmj.e2990 – ident: e_1_3_5_62_1 doi: 10.1016/j.beem.2023.101822 – ident: e_1_3_5_7_1 doi: 10.1097/AOG.0b013e3181ca4b3a – ident: e_1_3_5_93_1 doi: 10.1016/j.fertnstert.2014.03.004 – ident: e_1_3_5_53_1 doi: 10.1016/j.ejogrb.2016.05.009 – ident: e_1_3_5_29_1 doi: 10.1016/j.fertnstert.2016.09.027 – ident: e_1_3_5_15_1 doi: 10.3390/ph18010061 – ident: e_1_3_5_91_1 doi: 10.1136/jfprhc-2015-101375 – ident: e_1_3_5_87_1 doi: 10.1007/s00198-019-05103-6 – ident: e_1_3_5_74_1 doi: 10.3390/jcm11030810 – ident: e_1_3_5_48_1 doi: 10.2147/IJWH.S65481 – ident: e_1_3_5_98_1 doi: 10.1272/jnms.79.190 – ident: e_1_3_5_9_1 doi: 10.1097/GME.0000000000001427 – ident: e_1_3_5_28_1 doi: 10.1080/13625187.2023.2284085 – ident: e_1_3_5_19_1 doi: 10.1016/j.contraception.2016.04.014 – ident: e_1_3_5_33_1 doi: 10.1056/NEJMoa1111840 – ident: e_1_3_5_100_1 doi: 10.15585/mmwr.rr7304a1 – volume-title: Heavy menstrual bleeding: assessment and management. Number no. 88 in NICE Guideline year: 2021 ident: e_1_3_5_45_1 – ident: e_1_3_5_58_1 doi: 10.1016/s0010-7824(02)00473-0 – ident: e_1_3_5_37_1 doi: 10.1080/13625187.2002.11949332 – ident: e_1_3_5_66_1 doi: 10.1080/13625187.2024.2369833 – ident: e_1_3_5_4_1 doi: 10.4068/cmj.2018.54.3.153 – ident: e_1_3_5_57_1 doi: 10.1016/j.maturitas.2003.09.014 – ident: e_1_3_5_5_1 doi: 10.1097/gme.0b013e3181aa192d – ident: e_1_3_5_8_1 doi: 10.1016/s0029-7844(00)00930-3 – ident: e_1_3_5_46_1 doi: 10.1056/NEJMoa1204724 – ident: e_1_3_5_41_1 doi: 10.1002/14651858.CD002126.pub4 – ident: e_1_3_5_69_1 doi: 10.1155/2019/9701384 – ident: e_1_3_5_51_1 doi: 10.1097/AOG.0b013e3182118ac3 – ident: e_1_3_5_67_1 doi: 10.1080/13625187.2024.2332302 – ident: e_1_3_5_32_1 doi: 10.1177/2047487318774847 – ident: e_1_3_5_75_1 doi: 10.1016/j.contraception.2005.02.002 – ident: e_1_3_5_89_1 doi: 10.1080/13697137.2018.1540566 – ident: e_1_3_5_83_1 doi: 10.3109/09513590.2014.922947 – ident: e_1_3_5_82_1 doi: 10.3109/13625189709167466 – volume-title: UK Medical Eligibility Criteria for Contraceptive Use (UKMEC) year: 2019 ident: e_1_3_5_102_1 – ident: e_1_3_5_88_1 doi: 10.1007/s00404-015-3784-0 – ident: e_1_3_5_73_1 doi: 10.1016/0010-7824(95)00226-x – ident: e_1_3_5_54_1 doi: 10.1093/humrep/del162 – year: 2023 ident: e_1_3_5_2_1 publication-title: FSRH clinical guideline: contraception for women aged over 40 years – ident: e_1_3_5_76_1 doi: 10.2165/00003495-200363050-00003 – ident: e_1_3_5_25_1 doi: 10.20452/pamw.2128 – ident: e_1_3_5_85_1 doi: 10.1016/j.coemr.2023.100435 – volume: 83 start-page: 392 year: 1994 ident: e_1_3_5_14_1 article-title: Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism publication-title: Obstet Gynecol – ident: e_1_3_5_10_1 doi: 10.23736/S0026-4784.19.04469-1 – ident: e_1_3_5_78_1 doi: 10.1111/j.1743-6109.2011.02409.x – ident: e_1_3_5_16_1 doi: 10.1371/journal.pmed.1004326 – ident: e_1_3_5_18_1 doi: 10.1055/a-1919-9558 – ident: e_1_3_5_26_1 doi: 10.1016/j.contraception.2016.06.010 – ident: e_1_3_5_6_1 doi: 10.23736/S0026-4784.18.04291-0 – ident: e_1_3_5_68_1 doi: 10.1089/jwh.2016.5801 – ident: e_1_3_5_96_1 doi: 10.1097/AOG.0000000000000019 – ident: e_1_3_5_95_1 doi: 10.1093/humrep/deq043 – ident: e_1_3_5_34_1 doi: 10.1002/14651858.CD011054.pub2 – ident: e_1_3_5_38_1 doi: 10.1097/AOG.0000000000004899 – ident: e_1_3_5_23_1 doi: 10.1001/jama.2024.28778 – ident: e_1_3_5_56_1 doi: 10.1097/00003081-199538040-00019 – ident: e_1_3_5_47_1 doi: 10.1016/S0140-6736(00)03615-1 – ident: e_1_3_5_50_1 doi: 10.1080/13625187.2020.1731734 – ident: e_1_3_5_84_1 doi: 10.1080/13697137.2019.1632284 – ident: e_1_3_5_35_1 doi: 10.3389/fendo.2024.1428597 – ident: e_1_3_5_52_1 doi: 10.3109/01443615.2015.1024210 – ident: e_1_3_5_20_1 doi: 10.1111/aogs.14384 – ident: e_1_3_5_39_1 doi: 10.2196/63683 – ident: e_1_3_5_79_1 doi: 10.23736/S2724-606X.20.04688-2 – ident: e_1_3_5_90_1 doi: 10.1093/humrep/15.1.118 – ident: e_1_3_5_94_1 doi: 10.1093/humrep/dei457 – ident: e_1_3_5_92_1 doi: 10.1002/14651858.CD006033.pub5 |
| SSID | ssj0013436 |
| Score | 2.3991714 |
| SecondaryResourceType | review_article |
| Snippet | The objective is to develop expert consensus to inform clinical decision-making in the use of hormonal contraceptives in women over 40 years of age.
A... Objective: The objective is to develop expert consensus to inform clinical decision-making in the use of hormonal contraceptives in women over 40 years of age.... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 304 |
| SubjectTerms | Adult Birth control Consensus Contraception - methods Contraceptive Agents, Hormonal - administration & dosage Contraceptive Agents, Hormonal - adverse effects Female Hormonal Contraception - adverse effects Hormonal Contraception - methods Humans Italy Menstruation Middle Aged |
| Title | Consensus conference results on contraception in women beyond 40 years of age |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40838950 https://www.proquest.com/docview/3275520455 https://www.proquest.com/docview/3246412472 |
| Volume | 30 |
| WOSCitedRecordID | wos001554929600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAWR databaseName: Taylor & Francis Journals Complete customDbUrl: eissn: 1473-0782 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013436 issn: 1362-5187 databaseCode: TFW dateStart: 19960101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELa2BVW9IN4stJWRuK2ybNZObB8RouLSisMCe4scx1tFWpLVPqrS_9P_2RnbyW4oFXDgEkVxEiszX-wZz_gbQt7lySxXOfzfIlVJxItREeXghkRKx1bBFCRYwV2xCXF-LqdT9aXXu2n2wlzORVXJqyu1-K-qhmugbNw6-w_qbl8KF-AclA5HUDsc_0rxWIIT61esMKO8YZEFp3oz96EBl5yuQzYLLnc4EoZB7rey8NHgJ0jEJXjobp4QIqqzeB8M2e4LEUrIlOmIZDEtye-0dBTY24DHRaWNKX1G5YWd1y2MlptrzD4qG6Pa7CwYbFz5qcG3Er6oug51v13ykMayJjps2FmtNLIw7K5njJOd3BDrx2AuWISWy-4gHYI35Z0Rl_nqxXdmAp86GcP8nMRSDLGnIdKxiaRzP-hu8cMhgYMxKpVnwf2Fgrtp2iMPxiJROHhOTr9vg1UcI-DHodf3v-3zkBw0b-laQPe4Nc68mTwmj4JfQj94PD0hPVs9JQdnIfPiGTlrYUW3sKIBVrSuaAcFtKyogxX1sKJ8RB2saD2jIM_n5Ovpp8nHz1EoxREZxtQ6SnLJTMFNCp-WcpVbbQWyiOW8YCzmZgyG6sxIBf77KLdxrGXMpLBJkY6FUTBtvCD7VV3ZV4RKoa004EUYK7kVWoMLYfJYqZkoCiZEn_BGPJkJPPVYLmWexYHOthFwhgLOgoD7ZNg-tvBELX964KiRfRb-mVXGQL8JVmhI-uRt2wwjLobRdGXrDd7DU6zZLsZ98tLrrO2x0fHre1vekMMt6o_I_nq5scfkoblcl6vlCdkTU3ni4HULu3ehzg |
| linkProvider | Taylor & Francis |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Consensus+conference+results+on+contraception+in+women+beyond+40+years+of+age&rft.jtitle=The+European+journal+of+contraception+%26+reproductive+health+care&rft.au=Cagnacci%2C+Angelo&rft.au=Fruzzetti%2C+Franca&rft.au=Bruni%2C+Vincenzina&rft.au=Gambera%2C+Alessandro&rft.date=2025-12-01&rft.eissn=1473-0782&rft.volume=30&rft.issue=6&rft.spage=304&rft_id=info:doi/10.1080%2F13625187.2025.2544754&rft_id=info%3Apmid%2F40838950&rft.externalDocID=40838950 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1362-5187&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1362-5187&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1362-5187&client=summon |